Compare ADIL & FLGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADIL | FLGC |
|---|---|---|
| Founded | 2010 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8M | 7.6M |
| IPO Year | 2018 | 2021 |
| Metric | ADIL | FLGC |
|---|---|---|
| Price | $0.30 | $9.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.50 | N/A |
| AVG Volume (30 Days) | ★ 350.0K | 16.1K |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $57,609,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.13 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 24.71 |
| 52 Week Low | $0.22 | $6.80 |
| 52 Week High | $1.30 | $81.90 |
| Indicator | ADIL | FLGC |
|---|---|---|
| Relative Strength Index (RSI) | 41.89 | 46.42 |
| Support Level | $0.30 | $8.09 |
| Resistance Level | $0.33 | $13.70 |
| Average True Range (ATR) | 0.02 | 1.11 |
| MACD | 0.00 | 0.60 |
| Stochastic Oscillator | 47.05 | 34.80 |
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
Flora Growth Corp is a multi-national cannabis company that manufactures and distributes consumer packaged goods, cultivates and distributes medicinal cannabis, and distributes pharmaceutical products. Its reportable segments are: the commercial and wholesale segment (FGH and Cosechemos subsidiaries) and the house of brands segment (JustCBD, Vessel, and Kasa Wholefoods Company subsidiaries). Geographically, the company generates revenue from the United States, Germany, Australia, and the United Kingdom. It generates revenue as a distributor of pharmaceutical goods, and a manufacturer and reseller of a range of cannabis-based and complementary products.